Drug Profile


Latest Information Update: 14 Jan 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Proteome Systems
  • Developer Tyrian Diagnostics
  • Class Anti-ischaemics; Antidementias; Neuroprotectants; Small molecules
  • Mechanism of Action Oxygen radical scavengers; Superoxide dismutase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Adult respiratory distress syndrome; Autoimmune disorders; Myocardial ischaemia; Neurological disorders

Most Recent Events

  • 07 Nov 2001 This compound is still in active development
  • 23 Jun 1997 Preclinical development for Neurological disorders in USA (Parenteral)
  • 06 May 1997 Preclinical development for Adult respiratory distress syndrome in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top